|
Generic Name for INTUNIV
Guanfacine (as HCl) 1mg, 2mg, 3mg, 4mg; ext-rel tabs.
Legal Classification:
Rx
Pharmacological Class for INTUNIV
Central α2A-agonist.
Manufacturer of INTUNIV
Shire US, Inc.
|
Indications for INTUNIV
Attention deficit hyperactivity disorder (ADHD), as monotherapy or as an adjunct to stimulant medications.
Adult dose for INTUNIV
≥18yrs: not established.
Children's dosing for INTUNIV
Swallow whole with water, milk, or other liquid. Do not give with high-fat meals. <6yrs: not recommended. 6–17yrs: Initially 1mg once daily; titrate by 1mg/day at 1-week intervals; usual max 4mg once daily. Monotherapy: improvements seen at doses of 0.05–0.08mg/kg once daily; doses up to 0.12mg/kg once daily may provide additional benefit. Adjunctive therapy: optimal dosage range: 0.05–0.12mg/kg/day. Reevaluate periodically. Withdraw gradually (by 1mg every 3–7days).
Contraindications for INTUNIV
Concomitant use with other forms of guanfacine.
Warnings/Precautions for INTUNIV
Do not substitute with other forms of guanfacine on a mg-mg basis. Concomitant antihypertensives, other risks for hypotension, syncope, bradycardia, cardiovascular disease. Monitor heart rate, BP. Dehydration. Elevated temperature. Renal or hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
Interactions for INTUNIV
May be potentiated by CYP3A4/5 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers (eg, rifampin). May potentiate valproic acid. Additive effects with other antihypertensives, CNS depressants (eg, benzodiazepines, antipsychotics, barbiturates).
Adverse Reactions for INTUNIV
Somnolence, sedation, fatigue, nausea, lethargy, hypotension, insomnia, dizziness, abdominal pain, dry mouth, constipation; bradycardia.
How is INTUNIV supplied?
Tabs—100